as part of an ongoing series designed to highlight and review areas important to modern drug development ( Figure 1 ). Briefly introduced by Tom Kost ( GlaxoSmithKline ) and Michael Lotze ( University of Pittsburgh ), the focus was on the intersection of genomics, proteomics, and now ''viromics.'' The latter term refers to the use of viruses and viral gene transfer to explore the complexity arising from the vast array of new targets available from the human and murine genomes. Indeed, access to large numbers of genes using viral vectors is a key tool for drug discovery and drug delivery. With 38,000 genes identified within the human genome, only 5000 are considered readily druggable. Generating tools such as these to validate targets represents a major part of the armamentarium of the postgenomic scientist. During the last 12 years alone, there have been over 26,000 publications on virus vectors. Many of them have been found useful in target validation, assay development, and evaluation in in vivo models and gene therapy. Thus, there is now an extensive knowledge base for several viral vectors, with unique attributes within each of them providing versatility, efficiency, and ease of use. The individual scientists presenting at the meeting illustrated many of the unique and useful characteristics of such vector systems including retrovirus, adenovirus, herpes virus, simbis virus, and baculovirus.
Descriptive genomics, relational genomics, and biochemical approaches can all be used to develop an understanding of novel molecular targets. Any target that is identified through genomics will ultimately need to pass through a cellular physiology screen of biology and functional genomic analysis. There are several recent novel -enabling strategies where one can get at function without prior knowledge of an individual gene. For example, one can start with functional genomics screens using virally expressed cDNA or fragments of genes, do pathway mapping using yeast two -hybrid screens, and then follow up with proteomics. Target validation strategies such as these are necessary to select among new targets for drug discovery. Bioinformatics and a strong biologic intuition then become critically important in defining which of these targets is to be to pursued.
Focus on retroviruses
Nolan's laboratory has focused on retroviruses because he wants to stably incorporate the gene into the host cellular genome so that these genes will have long -term consequences including effects on resultant daughter cells. Further information from his group can be found on his web site, www.stanford.edu /group/ nolan. The Phoenix system they have developed uses highly transfectable suspension cultures of 293 cells, 1 which express env, gag -pol at high levels, budding out empty particles in the absence of any inserted genes. Using the retroviral LTR and insertion of a gene of interest in another plasmid transfected into these cells, one can derive nonreplicative but infectious particles expressing a gene of interest. One disadvantage of such Moloney retrovirus-based systems is that they can only deliver genes effectively into dividing cells. His laboratory has provided vectors to 4000 laboratories worldwide, 20 commercial ventures, and 4 human clinical gene therapy trials.
Retroviral libraries as tools
Garry then turned to the problem of the transcriptome. He can deliver whole libraries of 10 7 -10 8 genes in retroviral vectors and find the relevant gene product involved in a particular pathway or serving as a natural ligand using appropriate screening strategies. As an example, he focused on a screen of T-cell activation. The initiating step in T-cell activation is a consequence of TCR ligation. A variety of signal transduction steps with subsequent cellular responses occur distal to this event. Gene activation of kinases and transcriptional factors such as NFAT, secreted proteins such as IL-2, etc., are well known. He asked whether all the events in T-cell activation have been defined and whether there is enough detail to accurately define the T-cell activation pathways. As one example, he used surface activation of CD69 as a target readout, recognizing that other assays might give quantitatively or qualitatively different answers. He prefers the use of flow cytometric -based sorting claiming that it is a ''great genetic tool.'' One can readily identify cell surface molecules and kinases, and nuclear translocation events and then sort cells based on these properties. Following retroviral transfection of the Jurkat cell line with his library, he stimulated cells with anti -TCR, then recovered and expanded the desired cells. Sorting the CD69lo, CD3 + cells allowed identification of genes modifying CD69 expression. Doxacycline regulation of cDNA expression, using coexpression of tetracycline regulatable genes put into the library, turns the resultant gene /phenotype on or off. The inserted DNA in individual sorted cells can then be identified. Using an automated flow cytometric system with robotic control and three rounds of sorting, he defined a series of dox -regulatable phenotypes in clones after TCR stimulation. Multiple known inhibitors ( LCK, zap70, syk, plc1, pag /cbp, A -raf -1, SHP /PTP1C, CSK, nucleolin ) were identified. Expression of partial gene products interestingly can identify a dominant negative role of some otherwise stimulatory genes. He has also found seven novel genes including a serine /threonine kinase, a tyrosine phosphatase, a G -coupled protein receptor, and a ubiquitin ligase. Some of these can be inserted into primary cells and down -regulate stimulated IL -2 production.
Identification of peptides and peptidomimetics affecting signaling pathways
Another strategy, using such libraries, is to express peptides on the side chains of a molecule such as eGFP. This was a most interesting use of retrovirus to deliver organic molecules as ''peptides.'' Various peptide library motifs including free versus constrained peptide, linear peptides, pseudocyclic peptides, or cyclic peptides have been used 2 in such models to interact with cytosolic pathways. One can generate cyclic peptides, capturing shapes that inhibit one or another internal signaling pathway. 3 Such peptides can then be used to identify the number of molecules capable of interacting with a single target structure. Approximately 5% of sequences that he screened of both linear and constrained peptides localized to various cellular compartments, substantially different from that observed with eGFP with no peptide modification. His ultimate objective is to identify functional cyclic peptides. At least one of the peptides that they have synthesized so far and applied to cells directly recapitulates the phenotypes observed with the eGFPmodified constructs.
Using retroviruses to study HIV signaling
Nolan has also been interested in HIV1 entry into cells. Gilboa et al 4 worked out many of the mechanisms of reverse transcription several years ago. Some details, however, are just emerging. For example, in infected macrophages, the infection goes to culmination, eventuating in viral replication. Resting T cells do first strand transfer and, unlike macrophages, halt additional steps in viral replication until the T cell is activated. He 5 demonstrated that signaling induces an NFAT-dependent permissivity factor that is as yet undefined. The screen used cells transfected with NFAT driving the HIV-1 LTR, promoting expression of diphtheria toxin. An internal CMV promoter drove puromycin resistance and expression of the gene of interest. Following puromycin selection, clones surviving stimulation could then be placed in secondary assays to identify transfected cells that had died. Interactions involving critical cellular pathways were then identified in the rescued inserts. He obtained 50 different peptides that can inhibit the NFAT signaling pathway but not the NFB pathway. Interestingly, although holoenzymes may involve multiple proteins that interact over broad planar surfaces, he believes that there are allosteric sites on these protein complexes that can be inhibited by small organic molecules. An epistatic analysis of host proteins expressed during HIV-1 replication can be used to generate probes to identify and distinguish other signaling systems. For example, one of the peptides discovered, ''Pep80,'' inhibits TNF but not Fas-mediated apoptosis.
Cytokine and cytokine signaling pathways
A genetic screen to create peptide modifiers of cytokine pathways is also underway. For example, as a B cell starts to mature, it will switch from IgM to other downstream heavy chains, using recombination within the immunoglobulin locus. This opens up chromatin, making it accessible to switch recombination and allowing looping out and ligation of various VDJs with new effector constant regions. Peptide modifiers with a tetracycline regulatable promoter were created, which allowed screening of selected inhibitors, allowing direct determination of the levels of the peptide in as many as 10 10 cells. A total of 1500 primary hits were found on broader screening to reveal 400 that had specificity. The majority of the 400 peptides isolated specifically inhibit IL-4 induction of the endogenous " -promoter; many of these peptides can also inhibit primary B cells. Alanine scanning mutations introduced into these peptides modified their ability to inhibit the switch, correlating with yeast two hybrid -binding functions of the target genes identified. A novel protein that interacts with JAK3 was found this way.
Functional genomics
Novel tools for functional genomics in single cells can also be generated using concurrent polychromatic flow cytometry -based kinase assays. Measures of caspase activity, phospholipid content, PIP3 and PIP2 levels, and nuclear
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Viruses as gene delivery vectors MT Lotze and TA Kost translocation can all be performed together. Using this system, nearly all identified kinases can be followed by flow cytometry. P44/ 42 MAPK, p38 MAPK, JNK, AKT, PKC , PKC , RSK, and Mek can be followed after individual cell surface molecules are cross -linked. Addition of antibodies to ICAM2, CD28, and CD3 drive enhanced T-cell activation. He and his group can then perform a nine -dimensional analysis of T-cell activation with concurrent and sequential analyses of individual kinases. As a scientific founder of the biotechnology company Rigel, they will use such systems to go all the way through preclinical development. They are currently partners on some of this work with Pfizer, Novartis, and Janssen to apply these strategies in a variety of immune disorders, oncology, and infectious diseases. Baculoviruses are a diverse group of arthropod pathogens that drive lytic infection in their hosts. Following infection, an insect actually dissolves, melting into a local accumulation of high titer virus. These viruses are generally highly specific for individual insect species. They are indeed nonpathogenic for humans, which is an important safety factor in their widespread application as research tools. There are two identified genera: ( a) the nuclear polyhedrosis viruses (NPVs), and (b ) the granulosis viruses. Autographa californica NPV was used to develop vectors at GSK. The polyhedrin promoter is used to drive expression in Sf9 insect cells. Polyhedrin mRNA and the message encoding the protein of interest comprise about 25% of the polyA RNA and the subsequent protein in infected cells. Very good expression of GFP can be visualized in infected insect cells. The major advantages of recombinant baculoviruses are their ( a) unlimited capacity for large inserts and multiple expression cassettes; (b ) ease of use and scale up; (c ) ability to ultracentrifuge without loss of titer; ( d) posttranslational modification of proteins seen normally; and (e ) good biosafety profile. Budded virus is noninfectious for cells other than their natural hosts, avoiding inadvertent releases into the environment.
BacMam vectors
The so -called BacMam gene delivery system uses mammalian expression cassettes for the expression of heterologous proteins in mammalian cells. These viruses were first developed for pest control many years ago and led to the subsequent interest in replication within mammalian cells. Baculoviruses could infect cells but there was no evidence of gene expression or viral replication. In 1996 -1997, two reports demonstrated gene expression in cells of liver origin mediated by recombinant baculoviruses. 6, 7 Subsequent studies have advanced this viral system considerably. The GSK group uses a transposon system with a CMV promoter to express a gene of interest with a dominant selectable marker driving the neomycin resistance gene. 8, 9 They have also developed a PFastBac shuttle vector to easily clone in genes of interest from Escherichia coli and then go directly into insect Sf 9 cells with expansion of a viral stock. When the virus is added to mammalian cells, one observes only transient expression. This, indeed, was not seen as a major disadvantage in most of their systems. If one adds butyrate or trichostatin A, which inhibits histone deacetylase, this in turn leads to about a 30 -fold enhanced, but still transient, expression. Following selection with the neomycin analogue, G418, one can isolate stable expressing clones of interest at a reasonable frequency. They have had problems with transfection of hematopoietic cells including macrophage cell lines -Raw264.7, P388 -as well as other T-and B -cell lines that are poorly transduced. Different multiplicities of virus infection can be used to modulate expression going from 250 pfu / cell down to 1 pfu in transduced CHO cells and derive stable cell lines. About 1 /100 cells go on to form a stable cell line, each containing single integrants of BacMam cassettes. Upwards of 16 kb of a sequence can be inserted as nonspecific, random, and single integration events.
Using baculovirus to express HBV proteins
Normally, HBV will not infect cell lines but only transiently express in primary hepatocytes or fresh hepatoma cells. Standard reagents used in laboratories studying HBV include the HepG2.2.15 cell line, a hepatoma cell line stably transfected with HBV DNA. With BacMam infection, one can bypass all the steps necessary in normal viral entry and just deliver HBV DNA directly into the cell, launching an infection with pregenomic DNA. Within 48-96 hours of transfection using a plasmid CMV promoter placed upstream of a copy of the entire HBV genome, they were able to observe substantial levels of core and preS antigen. High levels of virus were detected in these cultures with several hundred -fold -greater level of gene expression of viral products. This system can also be used in other aspects of drug discovery including the generation of chimeric viruses or individual viral enzymes. For example, one can isolate polymerase active cores and add nucleoside triphosphates, observing incorporation of nucleotides to assay inhibitors of this enzyme. Demonstrating the superiority of this approach, they obtained 100-to 500 -fold -higher levels of polymerase active core particles than when using the standard HepG2 line. These cores provide a useful assay system for measuring kinetic parameters of cores from polymerase mutants. One can also generate a stable system, but in general, higher levels of HBV virions are produced from transduced, selected transient pools than from the HepG2 cell line. This system has been used to express all of the Hep C antigens but no particles have been observed as of yet, consistent with findings of others in the field. 
Baculovirus for nuclear hormone receptor screening

Baculovirus gene therapy
As gene therapy vectors, baculoviruses would be ideal, but for the fact that the virus is inactivated by complement. In vivo delivery, therefore, has great limitations. One could apply it in the liver or, e.g., in the brain, if delivered through the carotid artery or, as has been reported, with direct delivery into skeletal muscle. 10 A surface protein on the virus, gp64, is important for viral entry. Indeed, protein fusions and pseudotype virus can be created with this molecule. The receptor for this protein on insect and mammalian cells is not yet known. Neutralizing antibodies to the gp64 protein in animals that have been repeatedly dosed with the virus also limit its utility. There is a report of transduction of cultured neuronal cells, but with in vivo treatment, one observes delivery primarily into glial cells. showed that removal of ICP4 prevents productive viral replication; the ICP22 and ICP27 genes have also been eliminated from current generation vectors. With subsequent elimination of other immediate early genes, they can grow up to 10 9 -10 10 viruses /mL of media without apparent recombinants. ( d) Herpes establishes life -long quiescent state intracellularly as a final event -the virion is forced into the latent state and continues to express in latency a nonpolyadenylated transcript.
12,13
Herpes vector gene delivery -two strategies useful
One of the first approaches they considered using was direct delivery with stereotactic inoculation into neural parenchyma for Parkinson's disease and spinal root trauma. The second was peripheral inoculation to transduce sensory neurons in the dorsal root ganglia to treat neuropathy or pain. They have created vectors expressing BCL2 or glial derived neurotrophic factor ( GDNF ). Interesting neuroanatomic strategies can be used because of the long pathways; e.g., in Parkinson's disease models, one can put fluorogold beads into the CNS, which are then translocated and visualized in the substantia nigra. The vector can be injected at the same sites as the beads. The model they use applies the compound 6 -OH dopamine, which is toxic to dopaminergic neurons. Using this system, one can then determine if protective genes introduced by herpes vectors are capable of protecting the cells within the substantia nigra.
Interestingly, both gene products (bcl2 and GDNF ) are effective and additive. The presence of fluorogold indicates that the cell has survived. As a test of cell function, one can also measure the enzyme that is involved with the production of dopamine. Both bcl2 and GDNF prevent cells from dying and promote activity of the relevant enzyme, which is again additive for these two genes. Functionally, one can show that
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Proximal axonal injury model
The group modeled injury by injecting fluorogold into the sciatic nerve so that gold is carried back to the spinal cord. The roots were then traumatically severed and then the vector was injected into the dorsal horn. Both GDNF and bcl2 protected cells with this injury but, in this instance, there was no additive effect. Neural function was assessed by production of choline acetyl transferase. One observes loss of enzyme function with the lesion itself; GDNF and bcl2 applied together protected neurons from loss of enzyme activity but neither by themselves. They are currently testing whether animals have better motor function.
HSV -mediated gene transfer in peripheral neuropathy
The group could show that degeneration of sensory nerves in the skin resulted from a variety of conditions associated with neuropathy. In animal models, trophic factors including neurotrophin 3 and NGF protect these sensory nerves from neuropathy, but humans cannot tolerate doses sufficient to mediate important effects. NGF is effective in animal models at doses of 3 -5 mg /kg. In humans, at doses of 0.1 g/ kg, intolerable side effects were observed. In a large Phase II multicenter study, NGF at the maximally tolerable dose of 0.1 g /kg was ineffective in treating diabetic neuropathy. NGF binds to the high -affinity trkA receptor; NT3 binds to the trkC receptor. Both NT3 and BDNF interact with trkB. Fink's group made vectors expressing either NGF or NT3. Following application, one can detect NT3 made by the vector in the dorsal root ganglia. They then studied a model of sensory neuropathy due to 400 mg /kg pyridoxine administered intraperitoneally twice a day. NT3 in high doses given to rats prevents this neuropathy. Viral delivery also protects in these models. Evaluation of H -wave to monitor neural transmission requires an intact spinal arc. Although there is no complete preservation of H -wave, partial improvement with delivery of the vector is noted. Of particular interest is that one can see that larger fiber size neurons are protected. They can do the same thing in diabetic neuropathy, a more chronic animal models. Measuring loss of foot sensory amplitude, one can demonstrate that NGFexpressing vectors protect these neurons.
HSV -mediated inhibition of pain
Nociception occurs in the periphery, pain is perceived centrally, and there are pathways that block upward transmission to the brain of these so -called nociceptive stimuli. Opiate peptides work at the level of pre -and postsynaptic influences at the level of the spinal cord. Unfortunately, this is associated with numerous side effects including tolerance with continued use. They generated a herpes vector expressing the endogenous opiate, proenkephalin. When the virus is injected under the skin, one generates peptides within the cutaneous nerve endings that are then propagated proximally into the spinal cord. There are three different models of pain that they used.
Sensory nerve ligation
Ligation of the nerve causes drop out and loss of some nerve fibers, making other fibers that survive hyperexcitable. Allodynia develops, a condition defined as one in which usually innocuous stimuli are now painful. Graded sizes of von Frey hairs can be used to observe when animals respond with withdrawal with different levels of touch. Application of vector treatment shifts the curve back towards a normal response. Interestingly, the effect of the virus is continuous, lasting for several weeks, and one can reinject the virus expressing proenkephalin with reestablishment of the effect. This was surprising because use of vectors expressinggalactosidase predicted a much shorter period of expression. He believes that the result is obtained because of the high potency of the expressed peptides. As expected, its efficacy is blocked by intravenous naloxone.
Inflammatory pain
SHPE and morphine act synergistically in the SNL model of neuropathic pain. SHPE is antinociceptive despite tolerance to morphine, working at the level of the spinal cord. In inflammatory pain (formalin test ) models in which formalin is injected under the foot, the animal flinches and licks its paw. The delayed or late phase is markedly reduced by proenkephalin treatment delivered by an HSV vector with efficacy observed within 50 minutes after inoculation. Similarly, one observes reestablishment of the effect with repeat treatment limited to the ipsilateral site of injection.
Cancer pain
SHPE is antinociceptive in an osteogenic sarcoma model of cancer pain. Following injection of the NCTC 2472 tumor into the femur, bone pain arises. With injection of vector into the foot, substantial decreases in pain are observed. It is expected that pain arising from the femur should use the same nerve roots as those innervating the knee (L 2 , L 3 , L 4 ) in contrast with the foot ( L 3 , L 4 , L 5 ). Greater decrease in pain was observed when the vector was injected into the knee, which is consistent with the expected result. This preliminary data need to be confirmed in repeated experiments.
Martin Bachmann [ Cytos Biotechnology ]; Sindbis virus: From regulated gene expression to functional genomics
Sindbis virus exists under broad physiologic conditions. It normally shuttles from mosquitoes to birds and can infect a broad range of cell types. Initially, he discussed the reasoning for seeking regulated expression with this virus. They desired a temperature -sensitive process that allows growth to high cell densities and subsequently initiation of gene expression. Sindbis is simply a strand of RNA encapsidated by protein including the RNA replicase and a few other structural proteins. The replicase copies the negative strand RNA and, after second strand synthesis, subgenomic RNA is generated, which in turn encodes the various subunits of the Cancer Gene Therapy They developed a DNA -based replication cycle so that RNA replicase is positioned upstream of the gene of interest.
When transfected into cells, rapid transcription of the viral mRNA ensues, generating multiple copies of the viral message. They utilize a temperature -sensitive replicase variant, which was described many years ago. Initial ( À ) strand RNA production and then further replication with translation of second RNA occur only at the permissive temperature ( 348C). At 378C, they obtain absolutely no detectable expression. If they moved cultures to 308C, there is 1000 -fold up-regulation, which can be used to make a variety of proteins including -interferon at levels comparable to the most widely applied and optimized bioprocesses. When compared with the tetracycline regulatable system, differences of 4.4 -fold expression can be compared with those using the pCytTS -SEAP system, where one obtains 707 -fold up-regulation. Very toxic proteins can be expressed including the RIP death domain in stable viable cell lines maintained at 378C. Apoptosis is only induced at the permissive 298C temperature as demonstrated by Annexin staining. A mathematical model can indeed be generated to simulate balanced expression and degradation with good reliability as a logarithmic function of viral transfection, increasing nonlinearly. A series of differential equations measuring regulated expression can be used to determine the steady state level of mRNA, which is proportional to the square of the replicase activity. The major reason for such tight regulation is the presence of two replicative steps using the single RNA replicase. For example, using quantitative PCR with light cycler, he showed that genomic RNA is 120 -fold induced, subgenomic RNA is 80,000-fold induced, and protein is >20,000 -fold induced. If one examines the kinetics of the up-regulation, protein expression is delayed by 5 hours after induction of RNA. Comparing the test model with actual data, for the first 10 hours the model is a bit off, but afterwards it is quite robust. In other systems, only linear expression is obtained proportional with the level of infection. Once a certain threshold is hit with regulated RNA replicase, the expression increases quite dramatically.
Sindbis and genomics
DELphi technology is a merger of genomic sciences and high throughput screening, which they hope to develop for the pharmaceutical industry. Cytos' new functional screening approach is to be able to go from function to protein and then from protein to gene by expressing the entire transcriptome and then working back from phenotypes of interest. They had to modify the genome of the virus to enable it to be manipulated. Essentially, this was done by creating two fragments of RNA. One of these codes for the replicase, the other for the protein of interest. If one takes each plasmid and transfects them into cells by electroporation, expression is attained only if both plasmids are inserted. Two structural proteins separated from each other with the cDNA library of choice prevent recombination and splicing out of the DNA insert. They are confident that a single viral particle is sufficient to get full expression of one gene per cell. Like Nolan, they use flow cytometry to analyze cell surface expression. Their primary assays need binding of the protein to a surface receptor. Secreted membrane and intracellular proteins require more complex assay formats for functional screening such as proliferation or coagulation assays.
DELphi technology
This strategy is currently totally dependent on the quality of their libraries. Their current approach is to isolate RNA isolation using RNA easy followed by polyA selection, confirmed by Northern blot, first strand synthesis, and then second strand synthesis in some with primer extension. They only use PCR amplification where necessary. After Sfi1 digest, they perform size fractionation, then clone into virus. Large genes clone very badly. Small genes will always compete out larger genes in these types of libraries.
To get over this, they size fractionate and make essentially three separate libraries and then clone into viruses. The library with the larger fraction has an average of 3.2 kb size with the other two 1.95 and 1.05 kb, respectively, within the individual libraries. Successful capture varies with the different fractions, with the large genes only 50% and for the smallest, 81%. They have done extensive quality control and can find in most libraries genes comparable to those found in plasmid libraries. Currently, they infect cells at low MOI so that, on average, they obtain only one virus per cell. This is followed by application of fluoresceinated probes, which allows detection of ligand binding. Using their system, they found that it was important to exclude all dead cells with PI staining and to eliminate those nonspecifically binding the antibody probe. This system has been validated with the CD40 gene with confirmation by sequencing of the RT-PCR product. They were able to identify 104 cells that were sorted out of 100 million cells infected with the Sindbis library, 34 producing virus during amplification. Seven of these bound CD40L -Fc as evidence for successful capture of CD40. Use of the cell sorter allows them to screen 5 million cells per hour. CLOP lift assays are difficult to perform with mammalian cells. Petri dishes with a monolayer of cells can be infected with 50,000 plaques in a 15-cm plate. A physical link is generated between the gene and the protein in agarose semisolid media and secreted proteins are transferred onto nitrocellulose. For membranes, proteins need to wait 1 -2 days or longer to get them to diffuse through the agarose. They have screened for proteins that induce whole cell responses involved in coagulation, angiogenesis, or apoptosis. The advantage of this system is that they can obtain one novel protein per cell following transfection with the cDNA library at high efficiency.
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Normalized libraries
One of the problems with libraries cloned into such systems is that they tend to overrepresent common genes and less common genes can be lost or difficult to find. To reduce abundant genes, they used a photobiotinylated driver RNA and the same cDNA tester. Following hybridization at 16 hours at 428, abundant RNA find one another and are eliminated. This could be demonstrated with Rb or cdk2.
Genes of interest that were very rare in the original library could be identified after this procedure with increases in abundance 10 -100 fold. Examples included a transwell system to identify novel chemokines and so-called ''repellins'' for possible treatment of inflammation and autoimmune diseases. In addition to rediscovering known chemokines such as eotaxin, MCP-1, and others, they were able to identify at least one additional novel chemokine -like molecule. ; it then goes through the early endosome, a sorting endosome, and then across the nuclear membrane through nuclear pores. Fluorescent viruses demonstrate that infectious efficiency approaches 100%. Like other viruses, one can divide the genome into early genes and late genes, largely encoding the genes necessary for encapsidation. The E1 gene is essential for replication. In order to make a replication-incompetent vector, the E1 gene is deleted and propagated in complementing E1 + cell lines. 293 is the prototype cell line growing in suspension, which allows propagation of the virus to high levels. Up to 10 13 infectious viral particles can be obtained very easily. Given the ease and efficiency of production, such viruses could easily be used as novel drug -like therapeutic agents.
Trials and tribulations with adenovirus gene therapy; Hope for the future
If one critically examines the literature of gene therapy, one sees that retroviruses are used in 35% of studies, adenovirus in 28.3%, complexed plasmid DNA in 13%, and simple plasmid DNA in 12%, poxviruses in 7%, AAV in 3%, herpes simplex in 1% of patients, and all others amounting to no more than 1%. When gene therapy was first contemplated in man, the initial notion was that this would be applied to correct genetic diseases. One of the first gene therapy strategies to be tested was that in patients with cystic fibrosis. Using adenoviral vectors, and at intervals following delivery into patients, they collected airway epithelium and asked whether CFTR could be transferred effectively. 15 With the first infection, they obtained very high levels of expression. Following the second infection, expression diminished by one to two logs. No expression was observed after the third infection. Recently, however, work published from Yotnda et al 16 suggested that delivery of adenovirus coupled with liposomal encapsulation could obviate adenoviral immunogenicity with delivery plausible in the setting of neutralizing antibody. Stepwise development of such strategies, solving intrinsic problems of immunogenicity, has parallels with the early application of murine monoclonal antibodies, which required humanization to allow widespread development and commercialization. Alternatively, in patients with disorders in which transient expression is appropriate or when immune response to the virus is desired, one could consider application.
Application of adenoviral gene therapy in the setting of cardiovascular diseases
One possible strategy for use of adenoviruses is that of local delivery of factors to enhance tissue angiogenesis. 17 VEGF, for example, is critical for embryonic development of blood vessels. Its primary role is in the formation of new blood vessels during angiogenesis. VEGF is expressed as a single gene with differential splicing of four exons. They have focused on the 121 isoform (others include larger isoforms 165, 189, 206 ), although it is not clear if this is the best. This therapy could be used in the setting of diabetic retinopathy or 
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Viruses as gene delivery vectors MT Lotze and TA Kost neuropathy. A second strategy would be to apply such vectors in the setting of coronary artery disease. In a pig model of disease, ischemia was induced with a left circumflex constrictor. After 3 weeks, these animals had direct injection of the AdVEGF121 or control vector into the myocardium. After 4 weeks, pigs were evaluated for efficacy and safety. Without gene therapy, the artery was completely blocked by the constrictor as demonstrated by arteriography. Substantial collateral vessels were only produced in response to gene delivery of VEGF. Many of the new vessels are readily identifiable on the surface of the myocardium. 16 Following these results, clinical studies were initiated with virus delivered through a small anterior thoracotomy ( Chamberlain incision ) and injection of as many as 4Â10 9 viral particles directly into the wall of the heart. The selfreported angina class decreased in these patients after injection. The value of these assessments and this treatment awaits more formal Phase II assessments with a placebo group. In these patients, he injected virus into up to three areas in separate patients.
Dendritic cell delivery of cytokines
Local transgene expression can also be used to enhance an immune response. Many cytokines, when delivered systemically, are associated with substantial toxicity precluding doses necessary to observe efficacy based on what is predicted based on murine models. This is certainly true with systemic delivery of TNF that results in wasting and cachexia in murine models and in man. Using adenoviral delivery of TNF at doses up to 10 9 particles into tumors in animals, complete suppression of tumor growth was observed, but unfortunately a third of the treated mice died of cachexia and inanition. An alternative strategy was to enhance an immune response to tumor by expressing TNF in combination with DCs. This is a cell type important in initiating the immune response. Following capture of antigen, DCs under the influence of TNF mature and migrate to the regional lymph nodes to elicit immunity. Adenoviruses designed to express TNF were delivered into day 7 established tumors. Two days later, they would introduce intratumoral DCs. At the doses employed, neither DC alone had much of an effect, nor was the combination quite remarkable in suppressing tumor growth. 18 Quite prominent CD4 and CD8 infiltration was noted at the site of the regressing tumor. We have obtained similar results with delivery of IL -12 and IL -18 with DC. 19 -21 
